The findings support PERK downregulation as an integrative event facilitating dysregulation of RPE processes critical to cell survival known to contribute to AMD development and highlight PERK as a potential future therapeutic target for AMD. This evidence concerns the gene EIF2AK3 and age-related macular degeneration.